Objective A novel coronavirus emerged this year as a cause of viral pneumonia. The main characteristics of the virus are rapid transmission, high contagion capacity and potential severity. The objective of this case series study is to describe the clinical characteristics of patients with confirmed coronavirus disease (COVID-19) admitted to different intensive care units in Argentina for mechanical ventilation. Methods A descriptive, prospective, multicenter case series study was conducted between April 1 and May 8, 2020. Data from patients older than 18 years who were admitted to the intensive care unit for mechanical ventilation for acute respiratory failure with a positive diagnosis of COVID-19 were included. Results The variables for 47 patients from 31 intensive care units were recorded: 78.7% were men (median age of 61 years), with a SAPS II score of 43 and a Charlson index score of 3. The initial ventilatory mode was volume control - continuous mandatory ventilation with a tidal volume less than 8mL/kg in 100% of cases, with a median positive end-expiratory pressure of 10.5cmH 2 O. At the end of the study, 29 patients died, 8 were discharged, and 10 remained hospitalized. The SAPS II score was higher among patients who died (p = 0.046). Charlson comorbidity index was associated with higher mortality (OR = 2.27, 95% CI 1.13 - 4.55, p = 0.02). Conclusion Patients with COVID-19 and on mechanical ventilation in this series presented clinical variables similar to those described to date in other international reports. Our findings provide data that may predict outcomes.

No abstract

No abstract

Resumen. En este artículo se prueba la existencia de infinitos polinomios primos irreducibles unitarios sobre el cuerpo finito F q según Pollack a través de caracteres y series-L. Palabras clave: Caracteres, Series-L, fórmula de la inversión de Möbius. MSC2010: 11C02, 11N32, 12E10, 12Y02. Theorem of Dirichlet on F q [t]Abstract. In this paper we prove the existence of infinite unit irreducible prime polynomials on the finite field F q by Pollack through of characters and L-series Keywords: Characters, Series-L, Möbius inversion formula. IntroducciónLa progresión aritmética de números impares 1, 3, 5, . . . , 2k + 1, . . ., contiene infinitos números primos. Es natural preguntar si otras progresiones aritméticas tienen esta propiedad. Una progresión aritmética con el primer término a y diferencia común m consiste de todos los números de la forma a + mk, k = 0, 1, 2, . . . .Si a y m tienen un factor común d, cada término de la progresión es divisible por d y no puede haber más de un primo en la progresión si d > 1. En otras palabras, una condición necesaria para la existencia de infinitos números primos en la progresión aritmética (1) es que (a, m) = 1. Johann P. G. L. Dirichlet fue el primero en probar que esta condición es también suficiente. Esto es, si m > 0 y a son enteros con (a, m) = 1, entonces hay un número infinito de primos p en la progresión aritmética (1), es decir, un número infinito de primos p con p ≡ a mód m. Este resultado es conocido como el teorema de Dirichlet.0 *

Tigecycline is the first of a new class of antibiotics named glycylcyclines and is active in vitro against a variety of gram-positive and gram-negative organisms, including nosocomial resistant pathogens such as vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, extended-spectrum β-lactamase-producing Enterobacteriaceae, and multidrug-resistant- Acinetobacter spp. This medication has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia. Tigecycline's pharmacological and microbiological profile has also encouraged physicians’ to use the drug in other infections caused by resistant pathogens featuring limited therapeutics options (i.e. hospital-acquired pneumonia-HAP). In this study we publish the conclusions of an expert panel that identify and evaluate the evidence to support the use of Tigecycline in hospitalized patients with one of the following three infections: cSSSI, cIAI and HAP, including ventilator-associated pneumonia. Based on this data the panel developed an Algorithm Rational to Prescribe Tigecycline (ART) for each pathology.